KR102448642B1 - 칸나비노이드의 희석 제형 및 이의 제조 방법 - Google Patents

칸나비노이드의 희석 제형 및 이의 제조 방법 Download PDF

Info

Publication number
KR102448642B1
KR102448642B1 KR1020197012345A KR20197012345A KR102448642B1 KR 102448642 B1 KR102448642 B1 KR 102448642B1 KR 1020197012345 A KR1020197012345 A KR 1020197012345A KR 20197012345 A KR20197012345 A KR 20197012345A KR 102448642 B1 KR102448642 B1 KR 102448642B1
Authority
KR
South Korea
Prior art keywords
oil
cannabinoid
formulation
delete delete
cbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197012345A
Other languages
English (en)
Korean (ko)
Other versions
KR20190084035A (ko
Inventor
니심 가르티
샤론 가르티 레비
로템 에드리
Original Assignee
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. filed Critical 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디.
Publication of KR20190084035A publication Critical patent/KR20190084035A/ko
Application granted granted Critical
Publication of KR102448642B1 publication Critical patent/KR102448642B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Seasonings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
KR1020197012345A 2016-09-29 2017-09-28 칸나비노이드의 희석 제형 및 이의 제조 방법 Active KR102448642B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL248149 2016-09-29
IL248149A IL248149B (en) 2016-09-29 2016-09-29 Formulations of dilutable cannabinoids and processes for their preparation
PCT/IL2017/051097 WO2018061007A1 (en) 2016-09-29 2017-09-28 Dilutable formulations of cannabinoids and processes for their preparation

Publications (2)

Publication Number Publication Date
KR20190084035A KR20190084035A (ko) 2019-07-15
KR102448642B1 true KR102448642B1 (ko) 2022-09-28

Family

ID=57907589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012345A Active KR102448642B1 (ko) 2016-09-29 2017-09-28 칸나비노이드의 희석 제형 및 이의 제조 방법

Country Status (20)

Country Link
US (3) US11819490B2 (enExample)
EP (1) EP3518979B1 (enExample)
JP (2) JP7716071B2 (enExample)
KR (1) KR102448642B1 (enExample)
CN (1) CN110035774B (enExample)
AU (1) AU2017335722B2 (enExample)
CA (1) CA3038473A1 (enExample)
DK (1) DK3518979T3 (enExample)
ES (1) ES3021218T3 (enExample)
FI (1) FI3518979T3 (enExample)
HR (1) HRP20250547T1 (enExample)
HU (1) HUE072059T2 (enExample)
IL (1) IL248149B (enExample)
MX (1) MX2019003735A (enExample)
NZ (1) NZ752814A (enExample)
PL (1) PL3518979T3 (enExample)
PT (1) PT3518979T (enExample)
RS (1) RS66776B1 (enExample)
SI (1) SI3518979T1 (enExample)
WO (1) WO2018061007A1 (enExample)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL248150B (en) 2016-09-29 2018-05-31 Garti Nissim Method for selective extraction of cannabinoids from a plant source
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
IL248148B (en) 2016-09-29 2021-09-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd A method for extracting a compound from plant origin
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN110636834A (zh) * 2017-02-15 2019-12-31 分子浸剂有限公司 制剂
DK3651804T5 (da) 2017-07-11 2023-10-09 Aquanova Ag Solubilisat med curcumin, boswellia og xanthohumol
WO2020011854A1 (de) * 2018-07-11 2020-01-16 Aquanova Ag Solubilisat mit curcumin und zumindest einem cannabinoid als weiterem wirkstoff
US20190151280A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid Compositions
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
AU2019217673A1 (en) 2018-02-07 2020-09-24 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210008026A1 (en) * 2018-03-05 2021-01-14 Solva, Llc Water-soluble phytocannabinoid formulations
ES2973731T3 (es) * 2018-04-09 2024-06-24 Portland Tech Holdings Llc Extracto de cáñamo para el tratamiento del dolor en animales
CN112384212A (zh) 2018-05-03 2021-02-19 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、其组合物、方法和用途
RS64651B1 (sr) 2018-07-11 2023-10-31 Aquanova Ag Solubilizat ksantohumola
WO2020021543A1 (en) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol and curcumin for treating inflammatory diseases
JP2021534821A (ja) * 2018-08-20 2021-12-16 ヘクソ・オペレーションズ・インコーポレイテッド 制御されたカンナビノイドプロファイルのユーザー経験を有するカンナビス注入製品
US20210196670A1 (en) * 2018-08-27 2021-07-01 Emerald Health Therapeutics Canada Inc. Oral formulations of lavender and cannabinoids
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US11602504B2 (en) * 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
CA3118898A1 (en) * 2018-11-07 2020-05-14 Columbia Care Llc Sublingual and buccal dosage forms of cannabinoid extracts and method of use thereof
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
CA3128712A1 (en) * 2018-11-30 2020-06-04 Canopy Growth Corporation Water-soluble formulations of cannabinoids or cannabis-derived compounds, methods of making and use
EP4272731A3 (en) 2018-12-11 2024-02-14 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20200188298A1 (en) 2018-12-14 2020-06-18 NuVessl, Inc. Method For Using Composition With Enhanced Passenger Molecule Loading
WO2020132181A1 (en) * 2018-12-19 2020-06-25 Tilray, Inc. Cannabinoid formulations and pharmaceutical compositions
BR102018076973A2 (pt) * 2018-12-21 2020-09-15 Entourage Participações S.A. Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
CA3038349C (en) 2019-01-31 2021-04-13 Nam Hai LAI Process for producing a nano-cbd liposome system
CA3040532C (en) * 2019-04-17 2021-12-21 Medcan Pharma A/S Lozenge for improved delivery of cannabinoids
CN113966213B (zh) 2019-04-18 2024-08-27 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于亲脂性化合物的递送的自乳化药物递送系统
CN114007603A (zh) * 2019-04-24 2022-02-01 因美制药公司 用于使用大麻素进行神经保护的组合物和方法
KR102205207B1 (ko) * 2019-04-26 2021-01-20 주식회사 그린러쉬 농업회사법인 대마씨앗 추출물을 함유하는 음료 조성물
EP3969054A4 (en) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC OIL-SOLUBLE MEDICINAL COMPOSITIONS AND METHODS OF USE THEREOF
CA3141564A1 (en) * 2019-06-03 2020-12-10 Benuvia Manufacturing, Llc Cannabidiol nanocrystal compositions
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
CA3148277A1 (en) * 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a tubular flow reactor
US20220288014A1 (en) * 2019-08-08 2022-09-15 Neptune Wellness Solutions Inc. Oral formulations of cannabis extracts and methods of making same
US20230073516A1 (en) * 2019-08-09 2023-03-09 Ctc Science Inc. Intraoral fast-disintegrating formulation containing hemp oil extract or hemp powder extract as raw material of formulation
WO2021030250A1 (en) * 2019-08-10 2021-02-18 Locus Ip Company, Llc Methods for increasing the bioavailability of otc and pharmaceutical drugs
WO2021028917A1 (en) * 2019-08-13 2021-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Phytocannabinoids for preventing or treating non-alcoholic fatty liver disease, dyslipidemia, and type 2 diabetes
JP2022545491A (ja) * 2019-08-22 2022-10-27 イーピーエム（アイピー）， インコーポレイテッド カンナビノイド酸エステル組成物およびその使用
EP3782602A1 (en) * 2019-08-23 2021-02-24 NuVessl Inc. Composition with enhanced passenger molecule loading for use in a method for administration
AU2020342526A1 (en) * 2019-09-06 2022-03-24 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
AU2020340971A1 (en) * 2019-09-06 2022-03-17 Quicksilver Scientific, Inc. Microemulsion delivery systems for cannabis extracts and terpenes
KR20220061153A (ko) * 2019-09-06 2022-05-12 퀼실버 싸이언티픽, 인크. 비유도체화 호르몬을 포함하는 알코올-용해성 종에 대한 마이크로에멀젼 전달 시스템
WO2021055777A1 (en) * 2019-09-20 2021-03-25 Mycotechnology, Inc. Methods for reduction of bitterness in cannabinoids using mycelial materials
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
CA3150879A1 (en) * 2019-10-08 2021-04-15 Bessor Pharma, Llc Process for the production of cannabinoids and cannabinoid acids
CN114945360A (zh) * 2019-10-25 2022-08-26 心脏治疗公司 用于治疗心脏病的大麻二酚组合物
AU2020379674A1 (en) * 2019-11-04 2022-06-02 Landrace Bioscience Inc. Self-emulsifying cannabinoid formulation and method
CN110638756B (zh) * 2019-11-07 2021-10-08 辰风天然本草(北京)科技有限公司 一种含大麻二酚的组合物及其制备方法
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
MX2022007013A (es) 2019-12-09 2022-09-07 Nicoventures Trading Ltd Producto oral que comprende un canabinoide.
CA3162516A1 (en) * 2019-12-20 2021-06-24 Jiahua Zhou Emulsifying formulations of cannabinoids and/or cannabinoid extracts
UY39010A (es) * 2020-01-10 2021-08-31 Monsanto Technology Llc Composiciones de herbicidas de auxina que incluyen agentes retardantes de la deriva y métodos de preparacion de las mismas
WO2021155390A1 (en) * 2020-01-14 2021-08-05 Shaman Naturals, Llc. Antimicrobial compositions
CN113117092A (zh) * 2020-01-14 2021-07-16 中国科学院上海药物研究所 一种非水缓释递药系统
EP3871510A1 (en) * 2020-02-25 2021-09-01 Tapperwein Collection AG Medium chain triglyceride based oil phase in water microemulsions
EP4117641A1 (en) * 2020-03-09 2023-01-18 This Works Products Limited Compositions comprising functional fragrances and cannabis-derived compounds
CA3150881A1 (en) * 2020-05-04 2021-11-11 Anna PERSAUD Cannabinoid-comprising cosmetic compositions
WO2022011460A1 (en) * 2020-07-13 2022-01-20 Hexo Operations Inc. Transmucosal cannabis compositions with enhanced permeation properties
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2022091061A1 (en) * 2020-11-01 2022-05-05 Ai Pharmaceuticals Jamaica Limited Cannabis compositions and nanoemulsions
CN114515258B (zh) * 2020-11-20 2022-11-18 中国海洋大学 苯乙基间苯二酚纳米结构脂质载体、制备方法及在化妆品中的应用
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2022131394A1 (ko) * 2020-12-16 2022-06-23 주식회사 애드홈 칸나비디올 오일을 이용한 식물성 오일 에멀젼의 제조방법
CN112716897A (zh) * 2021-02-07 2021-04-30 澳门德诚生物科技有限公司 一种含纳米级大麻二酚的高度酒精饮料及其制备方法
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
DK181329B1 (en) 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
WO2022251707A1 (en) 2021-05-28 2022-12-01 Ananda Scientific, Inc. Methods for the treatment of post-traumatic stress disorder and traumatic brain injury with cannabinoids
US20230047027A1 (en) * 2021-07-13 2023-02-16 Demetrix, Inc. Compositions and methods using cannabinoid compounds for regulating gastric acid secretion to treat gastroesophageal reflux disease and related conditions
US20240316076A1 (en) * 2021-07-22 2024-09-26 Nicoventures Trading Limited Compositions comprising a constituent, derivative or extract of cannabis
CA3225825A1 (en) * 2021-07-22 2023-01-26 Steven Alderman Compositions comprising constituents, derivatives or extracts of cannabis
JP2023020034A (ja) * 2021-07-30 2023-02-09 株式会社東洋新薬 皮膚外用剤
WO2023072954A1 (en) * 2021-10-25 2023-05-04 Lipidor Ab Topical cannabinoid compositions
WO2023129153A1 (en) * 2021-12-29 2023-07-06 Pegasus Laboratories, Inc. Granular composition providing water dispersible cannabinoids and methods of making the same
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023215595A1 (en) * 2022-05-05 2023-11-09 Ananda Scientific, Inc. Methods for the treatment of anxiety disorder
AU2023375007A1 (en) 2022-11-01 2025-05-08 Aker Biomarine Human Ingredients As Phospholipid compositions for delivery of therapeutic compounds
KR20240150100A (ko) 2023-04-07 2024-10-15 주식회사 네오켄바이오 칸나비오르콜 또는 이의 유도체를 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2025196738A1 (en) * 2024-03-22 2025-09-25 Nanoprime Labs Corp Peg- and lecithin-free self-assembling microemulsions carrying cannabinoids and methods for use thereof
WO2025229641A1 (en) 2024-04-29 2025-11-06 Ananda Scientific, Inc. Methods for reducing nicotine and marijuana dependency by administration of cannabinoids

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155698A4 (en) 1999-01-29 2003-01-15 Nitto Kasei Co Ltd ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
IL165528A (en) 2002-06-12 2010-11-30 Yissum Res Dev Co Liquid concentrates of self-assembled nano-sized structures and their use as carriers for active components
JP2006511613A (ja) 2002-12-18 2006-04-06 アナコア ファーマシューティカルズ インコーポレイテッド ボロン酸複合体を含む抗生物質および使用法
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US20060217445A1 (en) 2003-07-25 2006-09-28 Chew Boon P Natural astaxanthin extract reduces dna oxidation
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US20160184258A1 (en) * 2005-11-07 2016-06-30 Murty Pharmaceuticals, Inc. Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
ES2581212T3 (es) * 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
WO2008058366A1 (en) 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
WO2008151136A1 (en) 2007-06-04 2008-12-11 Pressure Biosciences Inc. Pressure-enhanced extraction and partitioning of molecules
IT1394400B1 (it) 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
JP5149837B2 (ja) 2009-02-27 2013-02-20 Ｊｘ日鉱日石エネルギー株式会社 カロテノイドの製造方法
CN102145084A (zh) 2011-04-19 2011-08-10 宁夏医科大学 枸杞籽油自微乳化纳米组合物及其生产方法
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
CN103027863B (zh) 2011-09-30 2015-02-25 伽蓝（集团）股份有限公司 一种含有牡丹提取物的微乳液及其制备方法和应用
WO2013108254A1 (en) 2012-01-19 2013-07-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
EP2844243B8 (en) 2012-05-03 2019-12-18 Echo Pharmaceuticals B.V. Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol
US20140056828A1 (en) 2012-08-21 2014-02-27 Indiran Pather Novel formulations and uses for curcuma extracts
CH706963B1 (de) 2012-08-30 2016-03-31 Ai Fame Gmbh Verfahren zur Herstellung eines Cannabis enthaltenden Präparates.
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
CN103690580B (zh) 2013-11-07 2016-01-20 山西中医学院 穿心莲的微乳提取方法及其提取物
US9340475B2 (en) 2014-07-02 2016-05-17 Cv Sciences, Inc. Process for generating hemp oil with a high cannabidiol (CBD) content
ES2750750T3 (es) 2014-08-29 2020-03-27 Fuji Chem Ind Co Ltd Composición de emulsión
US10016363B2 (en) * 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9730911B2 (en) 2014-10-21 2017-08-15 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
HRP20211130T1 (hr) * 2015-03-02 2021-10-15 Medlab Clinical U.S., Inc. Transmukozni i transdermalni sustavi za isporuku
CA2982250A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
CN105535979B (zh) * 2015-11-22 2019-06-25 李素华 一种提高难溶药物生物利用度的自微乳化载药系统及其应用
US10342747B2 (en) 2015-12-16 2019-07-09 PPP&C Inc. Apparatus and method for preparing cosmeceutical ingredients containing epi-dermal delivery mechanisms
CA3011185A1 (en) 2016-01-20 2017-07-27 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
CN105535111B (zh) 2016-02-16 2019-06-28 山西汉麻生物科技有限公司 一种富含大麻二酚的火麻浸膏及其制备方法
CN105997985A (zh) 2016-06-14 2016-10-12 云南瑞酚生物科技有限公司 一种大麻提取物在制备治疗痛风药物中的应用
IL248148B (en) 2016-09-29 2021-09-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd A method for extracting a compound from plant origin
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
IL248150B (en) 2016-09-29 2018-05-31 Garti Nissim Method for selective extraction of cannabinoids from a plant source

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts

Also Published As

Publication number Publication date
CN110035774A (zh) 2019-07-19
RS66776B1 (sr) 2025-06-30
PT3518979T (pt) 2025-04-09
SI3518979T1 (sl) 2025-06-30
AU2017335722B2 (en) 2022-10-06
US20220008381A1 (en) 2022-01-13
US11819491B2 (en) 2023-11-21
HRP20250547T1 (hr) 2025-06-20
EP3518979A1 (en) 2019-08-07
CN110035774B (zh) 2022-11-29
KR20190084035A (ko) 2019-07-15
BR112019006106A2 (pt) 2019-06-18
AU2017335722A1 (en) 2019-05-16
JP2019532940A (ja) 2019-11-14
WO2018061007A1 (en) 2018-04-05
US20190314326A1 (en) 2019-10-17
ES3021218T3 (en) 2025-05-26
HUE072059T2 (hu) 2025-10-28
CA3038473A1 (en) 2018-04-05
DK3518979T3 (da) 2025-04-28
MX2019003735A (es) 2019-10-09
EP3518979B1 (en) 2025-03-12
US20240091192A1 (en) 2024-03-21
JP7716071B2 (ja) 2025-07-31
IL248149A0 (en) 2017-01-31
NZ752814A (en) 2022-07-29
FI3518979T3 (fi) 2025-06-03
IL248149B (en) 2020-03-31
US11819490B2 (en) 2023-11-21
PL3518979T3 (pl) 2025-07-07
JP2023109849A (ja) 2023-08-08

Similar Documents

Publication Publication Date Title
KR102448642B1 (ko) 칸나비노이드의 희석 제형 및 이의 제조 방법
KR102569534B1 (ko) 식물 공급원으로부터 칸나비노이드의 선택적 추출 방법
US20230094827A1 (en) Nanoemulsion compositions comprising biologically active ingredients
US20220088099A1 (en) Method for extraction of an agent from a plant source
US20220160731A1 (en) Compositions comprising biologically active agents and bile salts
JPWO2006106926A1 (ja) リグナン類化合物含有水中油滴型エマルション及びそれを含有する組成物
JP2016088912A (ja) Ｗ／ｏ／ｗ型エマルション
BR112019006106B1 (pt) Formulação farmacêutica ou nutracêutica carregada com canabinoide, e, composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4